Hepatic Involvement As Hyperbilirubinemia in Patients With Covid-19: Case Series From Iran Publisher Pubmed



Hormati A^{1, 2} ; Ghadir MR² ; Saeidi M³ ; Aminnejad R³ ; Afifian M⁴ ; Ahmadpour S² Show Affiliations
Source: Infectious Disorders - Drug Targets Published:2021

Abstract

Background: After the spread of novel coronavirus disease 2019 (COVID-19) from Wuhan to Iran, gastroenterology clinics were faced with a large number of patients who were suspected of being infected with the SARS-CoV-2. Among referred patients, the incidence of pure hyperbilirubine-mia as rare gastrointestinal (GI) symptoms was obvious. Methods: In this case series, we have reported the clinical data in detail of patients with COVID-19 who have been admitted to the Shahid Beheshti Hospital in Qom city, from 3rd March to 3rd August, 2020. COVID infection was confirmed by using real-time reverse-transcriptase polymerase chain reac-tion (rRT-PCR) and chest computed tomography (CT) scan. Results: According to the clinical findings, pure hyperbilirubinemia may be considered as a rare gastrointestinal (GI) symptom of COVID-19. However, it is possible that the other GI enzyme values fall in the normal range. Conclusion: In some infected patients, GI physicians may face hepatic involvement as pure hyperbili-rubinemia. During the present COVID-19 crisis, all GI physicians should be aware of the possible occurrence of hepatic involvement as an important prognosis of COVID pneumonia and it should be exactly addressed in newly referred patients to the GI clinic. © 2021 Bentham Science Publishers.